Drugs / VIO-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06257758 | Jan 2024 → Jan 2025 | breast cancer, ovarian cancer, prostate cancer | Valerio Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-22 | Valerio Therapeutics | Results Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial valeriotx.com ↗
No clinically significant adverse events or serious adverse events were reported and no MTD was declared. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-22 | Valerio Therapeutics | Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial valeriotx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VIO-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06257758 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT06257758 ↗ |